GSK’s ViiV Healthcare to increase HIV medicine access for children

Hannah Blake


GlaxoSmithKline’s HIV / AIDS company, ViiV Healthcare, has announced a collaboration with the Medicines Patent Pool (MPP). The MPP is the UN-backed public health mechanism created in July 2010 with the goal of increasing access to HIV medicines.

As part of this collaboration, Viiv Healthcare will grant MPP a voluntary license for paediatric formulations of the antiretroviral medicine abacavir in the 118 countries where most (98.7%) children living with HIV live.

ViiV Healthcare already has thirteen voluntary licence agreements with generics companies, all of which facilitate the manufacture and sale of low-cost versions of ViiV Healthcare medicines in those countries most affected by HIV and least able to pay for treatment and care.

“At ViiV Healthcare we have committed to playing our part to address the gaps in care and treatment of paediatric HIV. This agreement with the Medicines Patent Pool builds on the existing 13 licences granted to our generics partners and the broad range of initiatives supported through our Paediatric Innovation Seed Fund which aim to improve paediatric HIV research, care and treatment in resource-limited settings. The overarching goal of our efforts is to improve the lives of children living with HIV, and to help make ViiV Healthcare’s medicines available to them.”

Dr Dominique Limet, CEO, ViiV Healthcare.

In 2011, ViiV Healthcare and its licensees supplied an estimated 717 million antiretroviral tablets. This is the equivalent of around 12 months’ supply for over a million people living with HIV.

Approximately 3.4 million children are living with HIV worldwide, but 72% of those needing treatment do not have access to appropriate care and medicines.


Related news:

GlaxoSmithKline unit joins patent pool for AIDS drugs (Reuters)

Reference links:

ViiV Healthcare press release 

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.